NeonMind Biosciences Top Insiders
| NMDBFDelisted Stock | USD 0.50 0.00 0.00% |
NeonMind Biosciences employs about 6 people. The company is managed by 6 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Examination of NeonMind Biosciences' management performance can provide insight into the company performance.
| BA BA Insider CEO CoFounder |
| Tamara Melck Insider Chief Officer |
NeonMind |
NeonMind Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (1.8822) % which means that it has lost $1.8822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (37.2157) %, meaning that it generated substantial loss on money invested by shareholders. NeonMind Biosciences' management efficiency ratios could be used to measure how well NeonMind Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.NeonMind Biosciences Workforce Comparison
NeonMind Biosciences is considered to be number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 1,180. NeonMind Biosciences maintains roughly 6.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.
NeonMind Biosciences Notable Stakeholders
A NeonMind Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NeonMind Biosciences often face trade-offs trying to please all of them. NeonMind Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NeonMind Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| BA BA | CEO CoFounder | Profile | |
| Tamara Melck | Chief Officer | Profile | |
| Robert Tessarolo | Pres Chairman | Profile | |
| Ernie Ho | VP Devel | Profile | |
| CPA CGA | Chief Officer | Profile | |
| Trevor Millar | Advisor | Profile |
About NeonMind Biosciences Management Performance
The success or failure of an entity such as NeonMind Biosciences often depends on how effective the management is. NeonMind Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NeonMind management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NeonMind management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NeonMind Biosciences Inc. engages in the discovery, development, and commercialization of medicinal and psychedelic mushrooms for mental illnesses. NeonMind Biosciences Inc. is a subsidiary of The Yield Growth Corp. Neonmind Biosciences is traded on OTC Exchange in the United States.
NeonMind Biosciences Workforce Analysis
Traditionally, organizations such as NeonMind Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NeonMind Biosciences within its industry.NeonMind Biosciences Manpower Efficiency
Return on NeonMind Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 1.2M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in NeonMind Pink Sheet
If you are still planning to invest in NeonMind Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeonMind Biosciences' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |